Voyager Therapeutics, Inc. (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by stock analysts at Stifel Nicolaus in a research note issued to investors on Monday, Marketbeat reports. They presently have a $31.00 price target on the stock, up from their prior price target of $20.00. Stifel Nicolaus’ price objective indicates a potential upside of 34.20% from the company’s previous close.

Other analysts also recently issued reports about the company. Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, August 8th. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Chardan Capital reiterated a “hold” rating on shares of Voyager Therapeutics in a report on Sunday, September 10th. Evercore ISI started coverage on Voyager Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Raymond James Financial, Inc. started coverage on Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $27.86.

Voyager Therapeutics (NASDAQ:VYGR) traded down 2.94% on Monday, reaching $22.42. The company had a trading volume of 198,507 shares. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99. The stock’s 50-day moving average price is $18.58 and its 200 day moving average price is $11.86. The firm’s market capitalization is $603.17 million.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. On average, equities analysts anticipate that Voyager Therapeutics will post ($2.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/23/voyager-therapeutics-inc-vygr-price-target-raised-to-31-00-at-stifel-nicolaus.html.

In other news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the transaction, the insider now owns 17,157 shares of the company’s stock, valued at $171,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 32,940 shares of company stock worth $490,092 in the last ninety days. Corporate insiders own 8.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its position in shares of Voyager Therapeutics by 0.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock worth $261,000 after purchasing an additional 114 shares during the last quarter. Fiduciary Trust Co. lifted its position in shares of Voyager Therapeutics by 0.4% during the second quarter. Fiduciary Trust Co. now owns 109,034 shares of the company’s stock worth $977,000 after purchasing an additional 473 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after purchasing an additional 1,399 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Voyager Therapeutics by 8.4% during the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after purchasing an additional 2,000 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Voyager Therapeutics by 11.8% during the second quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock worth $334,000 after purchasing an additional 3,939 shares during the last quarter. 40.70% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.